APPLICATION OF RECOMBINED GANODERMA LUCIDUM IMMUNOMODULATORY PROTEIN (RLZ-8) IN PREPARATION OF DRUG FOR TREATING CHRONIC CARDIAC FAILURE

摘要

Disclosed is an application of recombined ganoderma lucidum immunomodulatory protein (rLZ-8) in the preparation of drugs for treating chronic cardiac failure. The invention employs Adriamycin (ADR) intraperitoneal injection to build a rat cardiac failure model for studying therapeutic action of rLZ-8 on chronic cardiac failure. The experimental study results show that rLZ-8 can obviously improve cardiac function of the rat chronic cardiac failure model, reduce the apoptosis rate of cardiac cells, and reduce expression of related apoptin (caspase3, caspase9) in cardiac cells, and increase the survival rate of rats with chronic cardiac failure.